Opinion

Video

Use of Molecular Biomarkers Tests

The panel examines the significance of biomarkers in assessing therapy outcomes for prostate cancer patients, while also exploring the concept of absolute benefit in metastasis risk when adding androgen deprivation therapy (ADT) to radiation therapy for newly diagnosed cases.

Video content above is prompted by the following question:

  • What role do biomarkers play in quantifying the benefits and risks of therapy for prostate cancer patients? (Angelo A. Baccala, MD)
    • Briefly discuss the use of molecular biomarkers tests, such as Prolaris, in predicting the absolute benefit in risk of metastasis of ADT added to radiation therapy in newly diagnosed prostate cancer patients.
Related Videos
Michael Jenson, PA-C, answers a question during a Zoom video interview
Couple talking with doctor | Image Credit: © Chinnapong - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.